PMA device
Innova Vascular Self-Expanding Stent System
Boston Scientific Corporation · Stent, Superficial Femoral Artery (NIP, Class III) · First FDA decision Jul 21, 2015, newest Dec 23, 2021Peripheral artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
6
Naming "Innova"
MAUDE reports
1,146
Brand "Innova", since 2015
PubMed studies
124
Mentioning "Innova"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Innova Vascular Self-Expanding Stent System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- Innova Vascular Self-Expanding Stent SystemPMA supplement
P140028-S070 · Decided Dec 23, 2021 · 83 days after receipt · Normal 180 Day Track
Device type: STENT, SUPERFICIAL FEMORAL ARTERY (NIP) · Cardiology
5 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Carotid Artery Stenting in Post-Approval StudiesNational analysisReview closedCAG-00259NUpdated Sep 17, 2026
- Carotid Artery StentingNational analysisReview closedCAG-00085RUpdated Sep 17, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Innova", any status and sponsor, newest update first.
Alder Hey Children's NHS Foundation TrustAcademic, hospital or other
NCT04629157 · 400 participants · Start Nov 5, 2020 · Primary completion Feb 1, 2021
Device: Innova Lateral Flow Device · For: This is a Pilot Study Which Aims to Assess the Validity and Applicability of Lateral Flow Assays (LFAs) Which Can be Used as a Point of Care Test for COVID-19; Covid19
Sites: Liverpool, United Kingdom; Manchester, United Kingdom
5 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Innova", and for the whole product code for context.
This brand
1,146 reports: 663 malfunction, 463 injury, 19 death
Whole product code NIP
9,363 reports: 4,911 malfunction, 4,303 injury, 147 death
Newest reports for this brand
- InnovaMalfunction
2124215-2026-56930 · Received Oct 27, 2026 · Event dated Oct 1, 2026
Device type: Stent, Superficial Femoral Artery (NIP)
Device problem as coded: Premature Activation
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0685-2018 · Started Nov 6, 2017 · Posted by FDA Feb 22, 2018
Reason given: Stent possibly unable to be fully released from the delivery system.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Stent, Superficial Femoral Artery (NIP)
1 more recall records with a free account
Published research
The most relevant PubMed records for "Innova"[tiab]. The summary above synthesizes these.
- Stent Design Affects Femoropopliteal Artery Deformation.
MacTaggart J, Poulson W, Seas A, et al. · Ann Surg · 2019Comparative Study, Evaluation Study
- Three-Year Clinical Outcomes of the Innovaࡊ Self-Expanding Nitinol Stent for the Treatment of Femoropopliteal Lesions.
Karashima E, Takahara M, Hozawa K, et al. · Cardiovasc Intervent Radiol · 2021Multicenter Study
- SARS-CoV-2 antigen lateral flow tests for detecting infectious people: linked data analysis.
Deeks JJ, Singanayagam A, Houston H, et al. · BMJ · 2022Evaluation Study, Multicenter Study
- Efficacy of Low-Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12-Month Randomised, Double-Blind, Placebo-Controlled Single-Centre Clinical Trial (INNOVA Study).
Rodríguez-Freire C, Navarrete J, Rozadilla-Sacanell A, et al. · Eur J Pain · 2026Randomized Controlled Trial
- A method of assessing peripheral stent abrasiveness under cyclic deformations experienced during limb movement.
Keiser C, Maleckis K, Struczewska P, et al. · Acta Biomater · 2022Research Support, N.I.H., Extramural
- Mapping pre-harvest sprouting resistance loci in AAC Innova × AAC Tenacious spring wheat population.
Dhariwal R, Hiebert CW, Sorrells ME, et al. · BMC Genomics · 2021
- Innova 2020: A Follow-Up Study of the Fecal Microbiota of Infants Using a Novel Infant Formula between 6 Months and 12 Months of Age.
Plaza-Diaz J, Ruiz-Ojeda FJ, Morales J, et al. · Int J Mol Sci · 2023
- Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study).
Colomer-Carbonell A, Sanabria-Mazo JP, Hernández-Negrín H, et al. · BMJ Open · 2022Clinical Trial Protocol, Research Support, Non-U.S. Gov't
- Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study.
García-Fiñana M, Hughes DM, Cheyne CP, et al. · BMJ · 2021Observational Study, Research Support, Non-U.S. Gov't
- Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study.
Eyre DW, Futschik M, Tunkel S, et al. · Lancet Infect Dis · 2023Observational Study, Research Support, Non-U.S. Gov't
- A Comparison Between Three Computer-Based Cone Specific Color Vision Tests.
Lovell J, Rabin J · Aerosp Med Hum Perform · 2023
- NITINOL MATERIAL PROPERTIES OF 11 COMMERCIAL PERIPHERAL STENTS DETERMINED USING INVERSE COMPUTATIONAL ANALYSIS.
Anttila E, Maleckis K, Jadidi M, et al. · bioRxiv · 2025Preprint
Other devices of this type
Also filed under product code NIP.
- GORE VIABAHN EndoprosthesisW. L. Gore & Associates, Inc. · PMA 2022
- Supera Peripheral Stent SystemAbbott Vascular (Idef Technologies Inc) · PMA 2025
- LifeStent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2023
- Everflex Self-Expanding Peripheral Stent System (Everflex)Medtronic Vascular, Inc. · PMA 2025
- BioMimics 3D Vascular Stent SystemVeryan Medical, Ltd. · PMA 2025
- Bard Lifestent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2016
- Astron Pulsar and Pulsar-18 Stent SystemsBiotronik AG · PMA 2018
- Misago Peripheral Self-Expanding Stent SystemTerumo Medical Corporation · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.